Jan Turek is a Sector Specialist in the Healthcare practice at Daybreak Capital Partners. Mr. Turek is also a Principal at TCG, a business development and interim management consulting firm specializing in medical devices, diagnostics and biotechnology.
Mr. Turek has 30 years of global experience in general management, product, business and market development as well as M&A/licensing with large and small pharmaceutical and biotechnology companies, working with small molecules, recombinant and plasma proteins. Most recently he spent 11 years as CEO of Biolex Therapeutics, a venture-backed company where he raised over $185 million to advance their pipeline.
Earlier in his career, Mr. Turek worked for 13 years at Bayer Pharmaceuticals, where he held senior country and international business positions in Canada, Germany and the US. He also held the position of Senior Vice President and General Manager of Bayer’s Biological Products Division, a $1 billion world-wide business with recombinant and plasma proteins focused on coagulation, respirology and immunology. He managed over 3000 people in research, development, production, finance, marketing and sales, and grew profits and sales through product line and geographic expansion strategies.
Mr. Turek graduated from McGill University (BSc, Biochemistry) in Montreal Canada.